{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Duration of response (calculated for responders only) was defined as time from the initial documented response (partial response or better) to confirmed disease progression, based on IMWG criteria.","groups":[{"description":"Participants received 4 mg pomalidomide administered by mouth on Days 1-21 of each 28-day treatment cycle and 40 mg dexamethasone (participants \\> 75 years of age received 20 mg dexamethasone) administered by mouth once per day on Days 1, 8, 15, and 22 of a 28-day cycle until disease progression.","id":"OG000","title":"Pomalidomide Plus Dexamethasone"}],"populationDescription":"Duration of Response was not analyzed as there was insufficient data available at Cycle 2, Day 1 of study treatment. There was limited data evaluated and data were not analyzed.","reportingStatus":"POSTED","timeFrame":"From first dose until the data cut-off date of 03 September 2014; maximum time for follow-up was 36 weeks","title":"Kaplan-Meier Estimates of Duration of Response","type":"SECONDARY"}